Clinical trial · Observational
NGS and TME for Evidence-based Treatment of Pancreatic Cancer
Evaluation of NGS in Combination With an Oncology Treatment Decision Support Software for Evidence-based Priorization of Individualised Treatment in Patients With Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The tumor tissue of patients with pancreatic cancer will be submitted to next-generation sequencing (NGS) and these data will be evaluated with an oncology treatment decision support (TDS) software tool that is a medicinal product class 1 (CE-marked). This software will make evidence-based suggestions for drugs likely to be effective, ineffective, or toxic (FDA approved biomarkers). For patients fit for second-line therapy, the resulting recommendations will be judged by the tumor board.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NGS | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of participants with technical success
- timeFrame
- 2 weeks
Secondary outcomes (1)
- measure
- Number of participants with actionable targets
- timeFrame
- 3 days
- description
- actionable targets (effective, ineffective, FDA approved toxicity markers)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patient age ≥ 18 years up to 75 years * Patient willing and able to provide informed consent * TreatmentMAP™ NGS/TME is ordered by the tumor board (MDT) under routine clinical practice * Diagnosis of a locally advanced, inoperable or metastatic pancreatic carcinoma, clinically and histologically verified according to the currently prevailing standards. * Patient received first line therapy according to applicable guidelines and/or standards (SoC) * Sufficient testing material available (e.g. tumor biopsy) to allow NGS/TME NGS panel testing. Exclusion Criteria: * Patients with ongoing systemic infection, * Patients with immunodeficiency, * Patients with severe cardiovascular and pulmonary morbidity that might interfere with or preclude further systemic anticancer treatment, * Patients on full therapeutic anticoagulation. * Patients who, due to their clinical status, are not eligible for further systemic anticancer therapy (chemotherapy, immunotherapy etc.) * Patients who, due to their disease status are in need of immediate therapy and cannot wait for the result of the NGS/TME process.
References
Publications (1)
- BACKGROUNDMalgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Gronberg H, Lohr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol. 2017 Oct;11(10):1413-1429. doi: 10.1002/1878-0261.12108. Epub 2017 Aug 8. PMID 28675654